Yenidoğan Dirençli Epilepsilerinde Nadir bir Olgu Sunumu: Piridoksamine-5′-Fosfat Oksidaz Eksikliği

Year 2025, Volume: 22 Issue: 4, 837 - 841, 25.12.2025

Leyla Şero , Nilufer Okur , Duygu Tunçel

https://doi.org/10.35440/hutfd.1667499

https://izlik.org/JA86CT25EU

Abstract

Piridoksine bağımlı epilepsiler (PBE), yenidoğan döneminde tekrarlayan nöbetlerin nadir bir nedeni olup antiepileptik ilaçların çoğuna dirençlidir. Tedavide piridoksine kısmı yanıt verirken Piridoksal 5'fosfat (P5P) nöbetleri durdurmada etkindir. Yenidoğan döneminde klinik özellikleri asfiksiyi taklit ettiğinden tanı koymak zorlaşabilir. Bu yazıda doğumdan sonra başlayan, antiepileptik ilaçlara yanıtsız dirençli miyoklonik nöbetlerle başvuran, piridoksine kısmi P5P'ye tam yanıt veren PBE tanısı ile izlediğimiz prematür bir kız bebeğin klinik ve genetik özelliklerini sunduk. PBE’ler antiepileptiklere dirençli nöbetleri olan her yenidoğanda mutlaka düşünülmeli ve terapötik dozda piridoksin ve Piridoksal 5’-fosfat tedavisine başlanmalıdır.

Keywords

Yenidoğan nöbetleri , Piridoksin bağımlı epilepsi , Vitamin B6 , Dirençli nöbetler

A Rare Case Report in Neonatal Refractory Epilepsy: Pyridoxamine-5′-Phosphate Oxidase Deficiency

https://izlik.org/JA86CT25EU

Abstract

Pyridoxine-dependent epilepsies (PDE) are a rare cause of recurrent seizures in the neonatal period and are resistant to most antiepileptic drugs. While pyridoxine is partially responsive,to treatment, Pyridoxal-5-Phosphate (P5P) is effective in stopping seizures. Diagnosis can be challenging in the neonatal period because its clinical features mimic hypoxic-ischemic encephalopathy. In this study, we present the clinical and genetic features of a preterm female infant who presented with postnatal refractory myoclonic seizures unresponsive to antiepileptic drugs and was followed with a diagnosis of PBE that was partially responsive to P5P and fully responsive to pyridoxine. PDE’s should be considered in every newborn with antiepileptic-resistant seizures, and treatment with therapeutic doses of pyridoxine and pyridoxal 5'-phosphate should be initiated.

Keywords

Neonatal seizures , Pyridoxine-dependent epilepsy , Vitamin B6 , Refractory seizures

References

• 1. Baxter P. Pyridoxine dependent and pyridoxine responsive seizures. Dev Med Child Neurol. 2001;43(6):416.
• 2. Jiao X, Gong P, Niu Y, et al. A rare presentation characterized by epileptic spasms in ALDH7A1, pyridox(am)ine 5′ phosphate oxidase, and PLPBP deficiency. Front Genet. 2022;13:804461.
• 3. Jaeger B, Abeling NG, Salomons GS, et al. Pyridoxine responsive epilepsy caused by a novel homozygous PNPO mutation. Mol Genet Metab Rep. 2016;6:60-63.
• 4. Guerin A, Aziz AS, Mutch C, et al. Pyridox(am)ine 5 phosphate oxidase deficiency: treatable cause of neonatal epileptic encephalopathy with burst suppression—case report and review of the literature. J Child Neurol. 2015;30(9):1218-1225.
• 5. Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med. 2006;12(3):307-309.
• 6. Al-Shekaili H, Ciapaite J, van Karnebeek C, Pena I. PLPBP Deficiency. In: GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993.
• 7. Pearl PL, Gospe SM Jr. Pyridoxalphosphatedependency: a newly recognized treatable catastrophic epileptic encephalopathy. J Inherit Metab Dis. 2007;30(1):2-4.
• 8. Raimondi F, Mills P, Clayton PT, Del Giudice E. A preterm neonate with seizures unresponsive to conventional treatment. BMJ Case Rep. 2015;2015:bcr2015209743.
• 9. Barile A, Nogués I, di Salvo ML, Bunik V, Contestabile R, Tramonti A. Molecular characterization of pyridoxine 5′ phosphate oxidase and its pathogenic forms associated with neonatal epileptic encephalopathy. Sci Rep. 2020;10(1).
• 10. Jiao X, Gong P, Niu Y, Zhang Y, Yang Z. A rare presentation characterized by epileptic spasms in ALDH7A1, pyridox(am)ine 5′ phosphate oxidase, and PLPBP deficiency. Front Genet. 2022;13:804461.
• 11. Mastrangelo M, Gasparri V, Bernardi K, Foglietta S, Ramantani G, Pisani F. Epilepsy phenotypes of vitamin B6-dependent diseases: an updated systematic review. Children (Basel). 2023;10(3):553.
• 12. Guerin A, Aziz AS, Mutch C, Lewis J, Go CY, Mercimek-Mahmutoglu S. Pyridox(am)ine 5 phosphate oxidase deficiency: treatable cause of neonatal epileptic encephalopathy. J Child Neurol. 2015;30(9):1218-1225.
• 13. Lugli L, Bariola MC, Ori L, Lucaccioni L, Berardi A, Ferrari F. Further delineation of pyridoxine responsive pyridoxine phosphate oxidase deficiency epilepsy: report of a new case and review of the literatüre with genotype-phenotype correlation. J Child Neurol. 2019;34(14):937-943.
• 14. Chi W, Iyengar ASR, Fu W, Liu W, Berg AE, Wu CF, et al. Drosophila carrying epilepsy associated variants in the vitamin B6 metabolism gene PNPO display allele and diet dependent phenotypes. Proc Natl Acad Sci U S A. 2022;119(9):e2115524119.
• 15. Yoshii A, Takeoka M, Kelly PJ, Krishnamoorthy KS. Focal status epilepticus as atypical presentation of pyridoxine dependent epilepsy. J Child Neurol. 2005;20(8):696-698.